William B Hawkins

Author:

William J. Hawkins

ISBN #:

0832302821

Author:

William G. Hawkins

ISBN #:

0405040202

Author:

William G. Hawkins

ISBN #:

0837120594

Author:

William R. Hawkins

ISBN #:

0936247150

Author:

William Hawkins

ISBN #:

0719101190

Author:

William Hawkins

ISBN #:

0824030796

Author:

William Hawkins

ISBN #:

0919813437

Author:

William Hawkins

ISBN #:

0887700829

US Patent:

7612085, Nov 3, 2009

Filed:

Jul 11, 2007

Appl. No.:

11/776533

Inventors:

Robert H. Mach - Eureka MO, US
Zhude Tu - Eureka MO, US
Wenhua Chu - St. Louis MO, US
Suwanna Vangveravong - Ballwin MO, US
Richard Hotchkiss - Chesterfield MO, US
William Hawkins - Olivette MO, US
Rebecca Aft - Chesterfield MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

A01N 43/42
A61K 31/44
C07D 221/02

US Classification:

514299, 546112, 546183

Abstract:

A series of N-substituted 9-azabicyclo[3. 3. 1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3. 3. 1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3. 3. 1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.

US Patent:

8143222, Mar 27, 2012

Filed:

Oct 22, 2008

Appl. No.:

12/255947

Inventors:

Jonathan E. McDunn - University City MO, US
William G. Hawkins - Olivette MO, US
Robert H. Mach - Eureka MO, US
Richard A. Hotchkiss - Chesterfield MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

A61K 38/02
A61K 38/16
C07K 2/00
C07K 14/00

US Classification:

514 189, 514 193, 514 213, 514 214, 530324, 530326, 530345, 530402

Abstract:

Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kof less than about 10M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.

US Patent:

8168650, May 1, 2012

Filed:

Aug 19, 2009

Appl. No.:

12/543647

Inventors:

Robert H. Mach - Eureka MO, US
Richard Hotchkiss - Chesterfield MO, US
William Hawkins - Olivette MO, US
Rebecca Aft - Chesterfield MO, US
Zhude Tu - Eureka MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514299

Abstract:

A series of N-substituted 9-azabicyclo[3. 3. 1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3. 3. 1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3. 3. 1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.

US Patent:

8461311, Jun 11, 2013

Filed:

Jun 8, 2011

Appl. No.:

13/155577

Inventors:

William G. Hawkins - Olivette MO, US
Dirk Spitzer - Webster Groves MO, US
Richard S. Hotchkiss - Chesterfield MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

C07K 14/52
C07K 14/47
C07K 16/46

US Classification:

530402, 530350, 530300, 530324, 5303873, 5303919, 514 189

Abstract:

Disclosed are TNF-related apoptosis-inducing ligand (TRAIL) trimers (TR3) and nucleic acids encoding covalently linked TRAIL trimers. A TRAIL trimer can have greater stability compared to native TRAIL, and can retain the native killing ability of TRAIL. Target specificity of a TR3 can be shown by blocking its activity with soluble death receptor 5 (DR5-Fc). Also disclosed are modified TRAIL trimers and nucleic. acids encoding them. These modifications include additional functional domains, such as antibody fragments (scFvs). A TR3 comprising an additional functional domain can allow for cell-specific delivery of the TR3. The inventors disclose TR3-decorated RBCs that target cell killing in a model of pancreatic cancer.

US Patent:

40120481, Mar 15, 1977

Filed:

May 2, 1975

Appl. No.:

5/574047

Inventors:

William R. Hawkins - Panorama City CA

Assignee:

Newcomb Audio Products Co. - Sylmar CA

International Classification:

G11B 360

US Classification:

274 39R

Abstract:

Concentric rings of acoustic damping material are mounted on a turntable surface and combine with an insulating adapter to provide acoustic isolation for records with large or small spindle holes. The rings are unconnected to prevent acoustic coupling between the rings while providing a flat surface on which a recording disc may be mounted. The adapter is formed of acoustic damping material and is resiliently mounted in the center of the turntable to be received by two different size spindle holes of various recording discs. The adapter is in the form of a disc having a thin annular section adapted to be received in a large spindle hole and an upstanding cylindrical section or boss of smaller diameter adapted to be received in a small spindle hole. The adapter is resiliently extended to normally position the annular section in the same plane as a recording disc mounted on the concentric rings. When a disc with a small spindle hole is placed on the concentric rings, its weight will bear upon the annular section of the adapter to reposition the adapter so that the boss is positioned in the plane of the recording disc to be received in the small spindle hole.

US Patent:

20180030109, Feb 1, 2018

Filed:

Oct 11, 2017

Appl. No.:

15/730441

Inventors:

Dirk Spitzer - Webster Groves MO, US
William G Hawkins - Saint Louis MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

C07K 14/705
C12N 15/63
C07K 14/47
C12N 15/62
A61K 38/17
C12N 15/74
A61K 38/19
C12N 15/70
A61K 38/00
C12N 15/79
C07K 14/525

Abstract:

Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.

US Patent:

20170022263, Jan 26, 2017

Filed:

Jul 13, 2015

Appl. No.:

14/798045

Inventors:

- Saint Louis MO, US
William G Hawkins - Olivette MO, US

International Classification:

C07K 14/705
C12N 15/62
C07K 14/47

Abstract:

Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.

Address:

1660 Tyson Dr, Florissant, MO 63031

Phone:

3148315770

VIN:

2GCEK13V071163632

Make:

CHEVROLET

Model:

SILVERADO 1500 CLASSIC

Year:

2007

Address:

4177 W Pt Loma Blvd, San Diego, CA 92110

VIN:

3GNDA13D07S579102

Make:

CHEVROLET

Model:

HHR

Year:

2007